logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Targeted Oncology cover

Targeted Oncology

IF4
Papers1208
Citations2514
Journal Papers 1204
Publication Date
delete
Claudin-18.2 in Gastric and Gastroesophageal Junction Adenocarcinoma: From Biology to Therapeutic Targeting: A Narrative Review
deleteTargeted Oncology
IF4
delete2026-08-14
delete0
PREAI
deleteRobin Grellet; Paul Rat; Olivier Facy; Nicolas Santucci
deleteShare
deleteSave
Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence
deleteTargeted Oncology
IF4
delete2026-08-12
delete0
deleteOAAI
deleteAnna Klimczak; Katarzyna Kisielewska; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
deleteShare
deleteSave
Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis
deleteTargeted Oncology
IF4
delete2026-08-07
delete0
deleteOAAI
deleteMattia Alberto Di Civita; Laura Pappalardo; Danila De Angelis; Marco Stellato; Luca Zacco; Simone Rota; Eleonora Gusmaroli; Valentina Guadalupi; Iolanda Speranza; Michela Roberto; Elena Verzoni; Giuseppe Procopio; Daniele Santini
deleteShare
deleteSave
P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast
deleteTargeted Oncology
IF4
delete2026-08-06
delete0
deleteOAAI
deleteHope S. Rugo; Joanne C. Ryan
deleteShare
deleteSave
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
deleteTargeted Oncology
IF4
delete2026-08-06
delete0
PREAI
deleteLuis Chinea; Caroline Hauer; Khushboo Pal; Hannah L. Chang; Isaac S. Chan
deleteShare
deleteSave
Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast
deleteTargeted Oncology
IF4
delete2026-08-06
delete0
deleteOAAI
deleteDanny Nguyen
deleteShare
deleteSave
FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials
deleteTargeted Oncology
IF4
delete2026-08-02
delete0
PREAI
deleteLiqiong Xue; Guopei Zhu; Peiguo Wang; Kunyu Yang; Yan Sun; Weidong Li; Zhendong Li; Cuihong Jiang; Qingqing Cai; Meiyu Fang; Man Hu; Minghua Ge; Wei Zhou; Sichen Li; Ye Guo
deleteShare
deleteSave
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)
deleteTargeted Oncology
IF4
delete2026-07-29
delete0
PREAI
deleteMimma Rizzo; Sebastiano Buti; Ondřej Fiala; Lorena Incorvaia; Javier Molina-Cerrillo; Maria T. Bourlon; Wataru Fukuokaya; Fumihiko Urabe; Se Hoon Park; Karl Mayrhofer; Renate Pichler; Dora Niedersuess-Beke; Tarek Taha; Thomas Büttner; Aristotelis Bamias; Emmanuel Seront; Daniele Santini; Luciano Stumbo; Alejo Rodriguez-Vida; Francesco Massari; Fernando Sabino Marques Monteiro; Andrey Soares; Enrique Grande; Matteo Santoni
deleteShare
deleteSave
Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years
deleteTargeted Oncology
IF4
delete2026-07-26
delete0
deleteOAAI
deleteMelanie Bathon; Nele Binder; Sabrina Welland; Christoph Gerdes; Thomas Wirth; Kristina I. Ringe; Markus Quante; Arndt Vogel; Anna Saborowski
deleteShare
deleteSave
From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board
deleteTargeted Oncology
IF4
delete2026-07-17
delete0
deleteOAAI
deleteTabea Fröhlich; Ulrich Lehmann; Tanja Reineke-Plaaß; Thomas Wirth; Sabrina Welland; Chen Du; Bernd Auber; Benjamin-Alexander Bollmann; Philipp Ivanyi; Tjoung-Won Park-Simon; Diana Steinmann; Christian Hartmann; Ariana de Oliviera Mekonnen; Anja Heutling; Andrea Schütte; Hans Heinrich Wedemeyer; Florian Heinrich Heidel; Susanne Isfort; Arndt Vogel; Anna Saborowski
deleteShare
deleteSave
Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA
deleteTargeted Oncology
IF4
delete2026-07-15
delete0
deleteOAAI
deleteMatthew S. Block; Ashley E. Stenzel; Rene Marcotte; Katrine L. Wallace
deleteShare
deleteSave
Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review
deleteTargeted Oncology
IF4
delete2026-06-30
delete0
deleteOAAI
deleteKoichi Goto; Hidetoshi Hayashi; Sonia S. Maruti; Heiko Zettl; Lalith Mittal; Smit Pathak; Xiuning Le
deleteShare
deleteSave
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies
deleteTargeted Oncology
IF4
delete2026-06-29
delete0
deleteOAAI
deleteAnikó Katalin Valikovics; Dániel Bacsó; Nadeen Samaien; Isabel Pinto Amorim das Virgens; Boglárka Szentes; Gergely Agócs; Mahmoud Obeidat; Tamás Széll; Boris Hadaschik; Péter Hegyi; Péter Nyirády; Tibor Szarvas
deleteShare
deleteSave
Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma
deleteTargeted Oncology
IF4
delete2026-06-15
delete0
deleteOAAI
deleteSai Sanikommu; Alejandro N. Santos; Bashar Dawoud; Khushi H. Shah; Sima Vazquez; Ashish H. Shah; Victor M. Lu
deleteShare
deleteSave
Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis
deleteTargeted Oncology
IF4
delete2026-06-08
delete0
deleteOAAI
deleteYen-Hsiang Huang; Kuo-Hsuan Hsu; Jeng-Sen Tseng; Po-Hsin Lee; I-Hung Lin; Mu-Han Peng; Tsung-Ying Yang
deleteShare
deleteSave
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker
deleteTargeted Oncology
IF4
delete2026-06-04
delete0
deleteOAAI
deleteHiroki Ishihara; Takayuki Nakayama; Hironori Fukuda; Nanaka Katsurayama; Yuki Nemoto; Shinsuke Mizoguchi; Hiroaki Shimmura; Yasunobu Hashimoto; Atsuko Seki; Kazuhiko Yoshida; Junpei Iizuka; Tsunenori Kondo; Yoji Nagashima; Toshio Takagi
deleteShare
deleteSave
Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?
deleteTargeted Oncology
IF4
delete2026-05-31
delete0
deleteOAAI
deleteMichael A. Liu; Kyle Miyazaki; Karie Runcie; Hanna Cash; Lingbin Meng
deleteShare
deleteSave
Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review
deleteTargeted Oncology
IF4
delete2026-05-30
delete0
deleteOAAI
deleteChin Hang Yiu; Gwyneth Yuet Yin Leung; Isabelle C. Lee; Christine Y. Lu
deleteShare
deleteSave
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power
deleteTargeted Oncology
IF4
delete2026-05-26
delete0
deleteOAAI
deleteVivek Subbiah; Martin Dietrich; Xiuning Le
deleteShare
deleteSave
Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial
deleteTargeted Oncology
IF4
delete2026-05-20
delete0
PREAI
deleteYu Sunakawa; Hisateru Yasui; Manabu Shiozawa; Hiroyuki Takeda; Naoya Akazawa; Tamotsu Sagawa; Kazuhiro Shiraishi; Takahisa Kyogoku; Takashi Mine; Yasuhiro Yuasa; Takanori Watanabe; Tatsuya Kinjo; Yoshihiro Okita; Hiroyuki Okuyama; Satoshi Yuki; Koki Miyakawa; Ayana Kobara; Shoko Yanaka; Yukiko Abe; Wataru Ichikawa; Masashi Fujii; Akihito Tsuji
deleteShare
deleteSave